Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a glaucoma eye drop also heal the cornea?

NCT ID NCT06960629

Disease control Sponsor: University Hospital Dubrava Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 01, 2026 · Last updated Sep 10, 2026 · Updated 7 times

Summary

This study tests whether a combination eye drop (netarsudil/latanoprost) can improve vision and reduce corneal thickness in people with glaucoma and a condition called pseudophakic bullous keratopathy, where the cornea swells after cataract surgery. Half of the 50 participants receive the active drops once daily for three months, while the other half receive placebo artificial tears. Researchers measure visual acuity and corneal thickness every two weeks to see if the drug helps.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Netarsudil/latanoprost eye drops
What this could lead to
If effective, these eye drops could offer a non-surgical way to improve vision and reduce corneal swelling in patients with glaucoma and pseudophakic bullous keratopathy.
What could go wrong
This is a small, early-stage trial with only 50 participants. The treatment may not prove better than placebo, and eye drops can cause irritation or redness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

50 people

The number who actually took part.

Started

May 2025

Finished

May 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * both sex, * age between 40 and 90 years * pseudophakic bullous keratopathy * glaucoma Exclusion Criteria: * other anterior segment pathology (corneal opacities); * ocular surface inflammation * retinal diseases affecting visual acuity * current treatment with topical prostaglandin analogue

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Glaucoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

bullous keratopathy corneal edema glaucoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Glaucoma Pseudophakic bullous keratopathy

Contacts and locations

Locations

  • University Hospital Dubrava

    Zagreb, Croatia, 10000, Croatia

More trials for these conditions

Other studies related to the condition(s) this trial covers.